CETP and Hypertension: It has been suggested that off-target effects of torcetrapib lead to increased activity of the renin-angiotensin-aldosterone-system (RAAS) and thereby hypertension [4], [20], but a recent review of the published CETP inhibitor clinical studies [21] concludes that the effect on blood pressure is most likely independent of the increase in aldosterone.